User:Sara Christine Norkelun/Sandbox 1
From Proteopedia
| Line 5: | Line 5: | ||
== Introduction == | == Introduction == | ||
| - | |||
| - | ---- | ||
Lyme disease is a systemic bacterial infection that can lead to chronic dehabilitating effects if left untreated. The symptoms are varied and affect multiple systems, sometimes making diagnosis difficult. Some initial symptoms are not unique to Lyme disease, and include fever, headache, lethargy, and soreness. The main identifying symptom is a characteristic bullseye rash that develops locally near the site of infection. If the infection is allowed to progress, more serious symptoms develop such as arthritis, swollen joints, and even neurological symptoms such as depression and psychosis. | Lyme disease is a systemic bacterial infection that can lead to chronic dehabilitating effects if left untreated. The symptoms are varied and affect multiple systems, sometimes making diagnosis difficult. Some initial symptoms are not unique to Lyme disease, and include fever, headache, lethargy, and soreness. The main identifying symptom is a characteristic bullseye rash that develops locally near the site of infection. If the infection is allowed to progress, more serious symptoms develop such as arthritis, swollen joints, and even neurological symptoms such as depression and psychosis. | ||
| Line 17: | Line 15: | ||
== VlsE and Immune Evasion == | == VlsE and Immune Evasion == | ||
| - | ---- | ||
The evasive nature of the pathogen ''Borrelia burgdorferi'' is believed to be due in part to its unique surface antigen, <scene name='User:Sara_Christine_Norkelun/Sandbox_1/Asymmetric_crystal_tetramer/2'>VlsE</scene>, or "Vmp-like sequence, Expressed". VlsE is a lipoprotein that is abundantly found on the membrane of the bacteria. It belongs to a class of proteins known as variable surface antigens, meaning that they are antigens located on the outer surface of the membrane, but are also of a variable nature. This unique variability is what is responsible for the proliferative nature of the bacteria in the human body, through its ability to evade immune recognition. | The evasive nature of the pathogen ''Borrelia burgdorferi'' is believed to be due in part to its unique surface antigen, <scene name='User:Sara_Christine_Norkelun/Sandbox_1/Asymmetric_crystal_tetramer/2'>VlsE</scene>, or "Vmp-like sequence, Expressed". VlsE is a lipoprotein that is abundantly found on the membrane of the bacteria. It belongs to a class of proteins known as variable surface antigens, meaning that they are antigens located on the outer surface of the membrane, but are also of a variable nature. This unique variability is what is responsible for the proliferative nature of the bacteria in the human body, through its ability to evade immune recognition. | ||
| Line 27: | Line 24: | ||
== Antibody Recognition == | == Antibody Recognition == | ||
| - | ---- | ||
| - | Antibody recognition is difficult, because genetic recombination is constantly altering the residues in the exposed variable regions, making the antigen appear different and unidentifiable Therefore, if an antibody does match a region on VlsE and binds, its effectiveness will become null once the bacteria produces a daughter cell with different variable regions. There is, however, a discrete region that has been shown to elicit an antibody response. The invariable region 6, or IR6, is one of the 6 invariable regions contained within the variable domain of the antigen. Serum samples from rhesus monkeys analyzed through a peptide based ELISA assay showed a strong antibody response to IR6. The antigenticity of this particular region was confirmed because none of the other IR regions (IR1-IR5) elicited an antibody response <ref name="Liang">Liang, F. T., Phillip, M. T. (1999) ''Infection and Immunity" 67:12 6702-6706.</ref>. | + | Antibody recognition is difficult, because genetic recombination is constantly altering the residues in the exposed variable regions, making the antigen appear different and unidentifiable Therefore, if an antibody does match a region on VlsE and binds, its effectiveness will become null once the bacteria produces a daughter cell with different variable regions. There is, however, a discrete region that has been shown to elicit an antibody response. The invariable region 6, or <scene name='User:Sara_Christine_Norkelun/Sandbox_1/Ir6_highlighted/2'>IR6</scene> |
| + | , is one of the 6 invariable regions contained within the variable domain of the antigen. Serum samples from rhesus monkeys analyzed through a peptide based ELISA assay showed a strong antibody response to IR6. The antigenticity of this particular region was confirmed because none of the other IR regions (IR1-IR5) elicited an antibody response <ref name="Liang">Liang, F. T., Phillip, M. T. (1999) ''Infection and Immunity" 67:12 6702-6706.</ref>. | ||
There is also an indication that the formation of <scene name='User:Sara_Christine_Norkelun/Sandbox_1/Dimer/1'>dimers</scene> in vivo may be responsible for some sheilding of the invariable regions at the connection between the two monomers<ref name="Eicken"/>. This may help to further explain why the invariable regions are so inaccessable to antibodies. | There is also an indication that the formation of <scene name='User:Sara_Christine_Norkelun/Sandbox_1/Dimer/1'>dimers</scene> in vivo may be responsible for some sheilding of the invariable regions at the connection between the two monomers<ref name="Eicken"/>. This may help to further explain why the invariable regions are so inaccessable to antibodies. | ||
| Line 35: | Line 32: | ||
== Structure == | == Structure == | ||
| - | ---- | ||
VlsE is composed of a variable domain flanked by two invariable domains. The invariable domain | VlsE is composed of a variable domain flanked by two invariable domains. The invariable domain | ||
| - | |||
| - | <scene name='User:Sara_Christine_Norkelun/Sandbox_1/Ir6_highlighted/2'>Ir6 Region</scene> | ||
<scene name='User:Sara_Christine_Norkelun/Sandbox_1/Aa_residues/1'>Amino acid residues</scene> | <scene name='User:Sara_Christine_Norkelun/Sandbox_1/Aa_residues/1'>Amino acid residues</scene> | ||
| Line 46: | Line 40: | ||
== Clinical Relevance == | == Clinical Relevance == | ||
ELISA test | ELISA test | ||
| - | + | ||
The IR6 region of VLsE is the basis of the C6 ELISA test, the first serological test for Lyme disease<ref name="LiangJCM">Liang FT, Steere AC, Marques AR, Johnson BJ, Miller JN, Philipp MT. 1999. Sensitive and specific serodiagnosis of Lyme disease by enzyme-linked immunosorbent assay with a peptide based on an immunodominant conserved region of Borrelia burgdorferi vlsE. ''J Clin Microbiol'' 37(12):3990-6.</ref>. IR6 has several qualities that make it a good antigen for an immunologic test: (1) most patients with Lyme produce detectable levels of antibody to IR6, (2) the antigenic epitope is conserved so that one test sequence suffices regardless of the strain of ''B. burgdorferi'' being tested for, and (3) the antibody is not generally found in patients without a history of Lyme, including those patients with diseases having similar symptoms and/or genetically related causative pathogens. These characteristics allow anti-IR6 antibody to be a sensitive test for Lyme disease, with 74% of acute phase infections and over 90% of convalescent and late-phase infections yielding positive results<ref name="LiangJCM"/>. Anti-IR6 antibody also results in good test specificity, with a 1.1% rate of false positives among patients with relapsing fever and autoimmune conditions (symptoms which can be mistaken for Lyme), patients with syphilis (caused by the sister genus to ''Borrelia''), and patients drawn at random from areas to which Lyme is not endemic<ref name="LiangJCM"/>. | The IR6 region of VLsE is the basis of the C6 ELISA test, the first serological test for Lyme disease<ref name="LiangJCM">Liang FT, Steere AC, Marques AR, Johnson BJ, Miller JN, Philipp MT. 1999. Sensitive and specific serodiagnosis of Lyme disease by enzyme-linked immunosorbent assay with a peptide based on an immunodominant conserved region of Borrelia burgdorferi vlsE. ''J Clin Microbiol'' 37(12):3990-6.</ref>. IR6 has several qualities that make it a good antigen for an immunologic test: (1) most patients with Lyme produce detectable levels of antibody to IR6, (2) the antigenic epitope is conserved so that one test sequence suffices regardless of the strain of ''B. burgdorferi'' being tested for, and (3) the antibody is not generally found in patients without a history of Lyme, including those patients with diseases having similar symptoms and/or genetically related causative pathogens. These characteristics allow anti-IR6 antibody to be a sensitive test for Lyme disease, with 74% of acute phase infections and over 90% of convalescent and late-phase infections yielding positive results<ref name="LiangJCM"/>. Anti-IR6 antibody also results in good test specificity, with a 1.1% rate of false positives among patients with relapsing fever and autoimmune conditions (symptoms which can be mistaken for Lyme), patients with syphilis (caused by the sister genus to ''Borrelia''), and patients drawn at random from areas to which Lyme is not endemic<ref name="LiangJCM"/>. | ||
| Line 55: | Line 49: | ||
== References == | == References == | ||
| - | + | ||
<references/> | <references/> | ||
Revision as of 02:58, 15 August 2012
Contents |
VlsE
Vmp-like sequence, Expressed
|
Introduction
Lyme disease is a systemic bacterial infection that can lead to chronic dehabilitating effects if left untreated. The symptoms are varied and affect multiple systems, sometimes making diagnosis difficult. Some initial symptoms are not unique to Lyme disease, and include fever, headache, lethargy, and soreness. The main identifying symptom is a characteristic bullseye rash that develops locally near the site of infection. If the infection is allowed to progress, more serious symptoms develop such as arthritis, swollen joints, and even neurological symptoms such as depression and psychosis.
The disease is caused by the bacterium, Borellia burgdorferi, the spirochete responsible for most Lyme disease in most of the Eastern region of North America. Borellia b. has a complex life cycle, transferring from different hosts. However, the main vector of disease transmission to humans is the deer tick, Ixodes scapularis, particularly the young nymph stage.
The main challenge to treatment of the disease is the bacteria's lengthy incubation time. After the time of entry, weeks may pass before symptoms begin to emerge, many of which are indistinguishable from more common maladies such as a cold or fatigue. During these initial weeks, Borellia burgdorferi is able to evade immune response for reasons which are not completely understood. It appears that this allows the bacteria to spread systemically and effect sites distal to the infection site, such as the joints.
VlsE and Immune Evasion
The evasive nature of the pathogen Borrelia burgdorferi is believed to be due in part to its unique surface antigen, , or "Vmp-like sequence, Expressed". VlsE is a lipoprotein that is abundantly found on the membrane of the bacteria. It belongs to a class of proteins known as variable surface antigens, meaning that they are antigens located on the outer surface of the membrane, but are also of a variable nature. This unique variability is what is responsible for the proliferative nature of the bacteria in the human body, through its ability to evade immune recognition.
VlsE may serve other unkown functions, but there is support for its role in immune evasion. If Borellia b. looses the encoding plasmid Ip28-1, which is responsible for the production of VlsE, the result is a significantly reduced degree of infection in the mouse model[1]. This property is a result of the antigen's complex structure, which is comprised of a proximal region which is presumably embedded in the bacteria's membrane, and an exposed distal region. The distal exposed region is the area of most interest, because it is comprised of small alternating variable and invariable regions. While the invariable regions maintain a constant composition between generations of bacteria, the variable regions undergo a complex gene recombination mechanism which alters the variable regions between generations[2]. These rapid modifications in the variable regions may confer the bacteria with a kind of protection from immune recognition. The constantly changing variable regions on the exposed surface may act as a mask, preventing antibodies from making a reliable identification.
Antibody Recognition
Antibody recognition is difficult, because genetic recombination is constantly altering the residues in the exposed variable regions, making the antigen appear different and unidentifiable Therefore, if an antibody does match a region on VlsE and binds, its effectiveness will become null once the bacteria produces a daughter cell with different variable regions. There is, however, a discrete region that has been shown to elicit an antibody response. The invariable region 6, or , is one of the 6 invariable regions contained within the variable domain of the antigen. Serum samples from rhesus monkeys analyzed through a peptide based ELISA assay showed a strong antibody response to IR6. The antigenticity of this particular region was confirmed because none of the other IR regions (IR1-IR5) elicited an antibody response [3].
There is also an indication that the formation of in vivo may be responsible for some sheilding of the invariable regions at the connection between the two monomers[2]. This may help to further explain why the invariable regions are so inaccessable to antibodies.
Structure
VlsE is composed of a variable domain flanked by two invariable domains. The invariable domain
Clinical Relevance
ELISA test
The IR6 region of VLsE is the basis of the C6 ELISA test, the first serological test for Lyme disease[4]. IR6 has several qualities that make it a good antigen for an immunologic test: (1) most patients with Lyme produce detectable levels of antibody to IR6, (2) the antigenic epitope is conserved so that one test sequence suffices regardless of the strain of B. burgdorferi being tested for, and (3) the antibody is not generally found in patients without a history of Lyme, including those patients with diseases having similar symptoms and/or genetically related causative pathogens. These characteristics allow anti-IR6 antibody to be a sensitive test for Lyme disease, with 74% of acute phase infections and over 90% of convalescent and late-phase infections yielding positive results[4]. Anti-IR6 antibody also results in good test specificity, with a 1.1% rate of false positives among patients with relapsing fever and autoimmune conditions (symptoms which can be mistaken for Lyme), patients with syphilis (caused by the sister genus to Borrelia), and patients drawn at random from areas to which Lyme is not endemic[4].
Picture from wiki entry on ELISA
References
- ↑ Labandiera-Rey, M., Baker, E., and Skare, J. T. (2001) J. Infect. Immun. 446-455.
- ↑ 2.0 2.1 Eicken, C., Sharma, V., Klabunde, T., Lawrenz, M. B., Hardham, J. M., Norris, S. J., and Sacchettini, J. C. (2002) J. Bio. Chemistry 227:24 21691-21696.
- ↑ Liang, F. T., Phillip, M. T. (1999) Infection and Immunity" 67:12 6702-6706.
- ↑ 4.0 4.1 4.2 Liang FT, Steere AC, Marques AR, Johnson BJ, Miller JN, Philipp MT. 1999. Sensitive and specific serodiagnosis of Lyme disease by enzyme-linked immunosorbent assay with a peptide based on an immunodominant conserved region of Borrelia burgdorferi vlsE. J Clin Microbiol 37(12):3990-6.
